Baxter International (BAX) Expected to Announce Earnings on Thursday

Baxter International (NYSE:BAX) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 13th. Analysts expect Baxter International to post earnings of $0.52 per share and revenue of $2.67 billion for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Friday, November 8th. The medical instruments supplier reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Baxter International had a net margin of 0.77% and a return on equity of 18.30%. The business had revenue of $3.85 billion during the quarter, compared to analysts’ expectations of $3.85 billion. During the same period last year, the company posted $0.68 earnings per share. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, analysts expect Baxter International to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Baxter International Trading Up 0.1 %

NYSE BAX opened at $31.47 on Thursday. The company has a market capitalization of $16.07 billion, a PE ratio of 157.33, a price-to-earnings-growth ratio of 10.39 and a beta of 0.61. Baxter International has a 1-year low of $28.33 and a 1-year high of $44.01. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31. The firm’s fifty day simple moving average is $30.90 and its 200-day simple moving average is $34.51.

Baxter International Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Investors of record on Friday, November 29th were issued a $0.17 dividend. The ex-dividend date of this dividend was Friday, November 29th. This represents a $0.68 dividend on an annualized basis and a yield of 2.16%. Baxter International’s dividend payout ratio is currently 340.00%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BAX. Stifel Nicolaus reduced their price objective on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Citigroup cut their price objective on Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. Finally, StockNews.com cut Baxter International from a “buy” rating to a “hold” rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $40.45.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.